XOMA Reports Fourth Quarter and Full Year 2018 Financial Results and Operating Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
XOMA (XOMA) Tops Q4 EPS by 14c, Revenues Beat
March 7, 2019 7:19 AM ESTXOMA (NASDAQ: XOMA) reported Q4 EPS of ($0.35), $0.14 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $1.55 million versus the consensus estimate of $1.13 million.
In 2018, we completed the first transaction under our royalty-aggregator business model, adding seven assets being developed by Merck and Incyte, bringing our royalty... More
